NEW YORK (GenomeWeb News) – Foundation Medicine today reported unaudited total revenue of $29 million for the year ended Dec. 31, 2013, compared to less than $11 million for 2012.

The company's preliminary revenues beat consensus analyst estimates for the year of $28 million.

Oncologists ordered around 3,750 FoundationOne clinical tests in the fourth quarter, compared to 2,577 for the year-ago quarter. For the whole year, oncologists ordered 9,000 tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.